Wedbush Downgrades Meridian Biosciences (VIVO) to Underperform as Competitor Gains Momentum
Tweet Send to a FriendGet Alerts VIVO Hot Sheet
Price: $21.89 +1.06%
Rating Summary:
3 Buy, 4 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
3 Buy, 4 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade VIVO Now!
Wedbush downgraded Meridian Biosciences (NASDAQ: VIVO) from Neutral to Underperform with a price target of $17.00 on poor risk/reward.
"We are hearing from industry sources that Great Basin, a private molecular diagnostics company with a recently launched C.diff test, is gathering momentum," the analyst comments. "Great Basin, who launched its "sample-in answer out" platform and FDA approved C.diff test in July 2012, is winning accounts (mostly sub 300 bed hospitals) based on its easy-to-use test, low price point (low $20s) and free system. As a result, we are more cautious on VIVO's c.difficile business (~22% of sales) for 2013, where we are modeling 50 system placements/q in 2013 and a slight decline in utilization per quarter, exiting the year near 1400 tests/system (annualized).
Based primarily on C.difficile deceleration in 2013 & 2014, Wedbush now forecast $186 MM and $197 MM with EPS of $0.86 and $0.92 versus consensus estimates of $190 MM and $209 MM with $0.88 and $1.00 EPS in 2013 and 2014, respectively.
For an analyst ratings summary and ratings history on Meridian Biosciences click here. For more ratings news on Meridian Biosciences click here.
Shares of Meridian Biosciences closed at $20.56 yesterday, with a 52 week range of $16.19-$21.06.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
"We are hearing from industry sources that Great Basin, a private molecular diagnostics company with a recently launched C.diff test, is gathering momentum," the analyst comments. "Great Basin, who launched its "sample-in answer out" platform and FDA approved C.diff test in July 2012, is winning accounts (mostly sub 300 bed hospitals) based on its easy-to-use test, low price point (low $20s) and free system. As a result, we are more cautious on VIVO's c.difficile business (~22% of sales) for 2013, where we are modeling 50 system placements/q in 2013 and a slight decline in utilization per quarter, exiting the year near 1400 tests/system (annualized).
Based primarily on C.difficile deceleration in 2013 & 2014, Wedbush now forecast $186 MM and $197 MM with EPS of $0.86 and $0.92 versus consensus estimates of $190 MM and $209 MM with $0.88 and $1.00 EPS in 2013 and 2014, respectively.
For an analyst ratings summary and ratings history on Meridian Biosciences click here. For more ratings news on Meridian Biosciences click here.
Shares of Meridian Biosciences closed at $20.56 yesterday, with a 52 week range of $16.19-$21.06.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: MKM Partners Downgrades Alkermes (ALKS) to Sell
- Wedbush Downgrades salesforce.com (CRM) to Neutral
- TD Securities Downgrades Nordion Inc (NDZ) to Reduce
Create E-mail Alert Related Categories
Analyst EPS Change, Downgrades, Hot Downgrades
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
